With Help From The Yield Lab, Aptimmune Biologics Gains Access to the Worldwide Market

Estimated reading time: 2 minute(s)

Aptimmune Biologics, a member of the 2016 Yield Lab portfolio of AgTech startups, announced their partnership with Kemin Industries, an Ag and Animal product manufacturer headquartered in Des Moines, Iowa for world-wide distribution. As of July 31, 2018, Kemin is now an equity shareholder in Aptimmune and has exclusive rights to its vaccines and vaccine technologies outside the U.S.

Aptimmune is an example of an AgTech company which was successfully lured to St. Louis through a combination of matched public and private investment capital and ESO support and incubation. Last year, the company raised $6 million Series B investment from the Missouri Technology Corporation and the St. Louis Arch Angels and participated in the Yield Lab accelerator program.

Aptimmune’s close ties with the Yield lab has certainly influenced the company’s direction and decisions. In early 2008, Aptimmune moved their headquarters from Champaign, Illinois to BRDG Park on the Donald Danforth Plant Science Center campus, 39 North. Bob Nordgren, a Yield Lab Managing Director with years of experience in animal vaccines, works with Aptimmune as an investor and embedded c-suite consultant.

According to Bob Nordgren,”the attractiveness of working with companies such as Aptimmune was a large factor in my decision to join the Yield Lab team.”

The joint partnership creates Kemin Biologics, which will manufacture and market Aptimmune’s proprietary Barricade™ swine vaccine technology and products outside the U.S. Apitimmune’s portfolio of mucosal vaccines (as opposed to injectables) provides a far superior inoculation against many problematic viral diseases impacting the swine industry, such as the Porcine Reproductive and Respiratory Syndrome virus (PRRSV) and influenza.

According the National Pork Board, the impact of PRRSV alone to productivity in the U.S. swine market was estimated at around $580 million in 2016, a steady decline from a high of $663 Million year upon year since 2010 due in large part to technological advances in vaccines and animal care.

Previous articleITEN’s CIP Program Jumpstarts Corporate Innovation
Next articleThe Bourbon Friday Show with Assistive Technology Creator Key2Enable
blank
Stories published by EQ Staff indicate that the article has been produced by multiple authors or adapted from a press release that's been sent to the editorial team. Press releases are not paid for placements and are selected for publishing on a merit basis. The best press releases contain useful advice, announcements, information or news that is relevant to our readers. We always check our email so if you'd like to submit a press release for consideration please feel free to drop us a line.